Attenuated Inflammatory Response in Laparoscopic Colon Surgery

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Dag T Førland, Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT01419431
First received: July 18, 2011
Last updated: December 15, 2011
Last verified: December 2011
  Purpose

Pro-inflammatory responses following laparoscopic surgery.


Condition Intervention
Regulation of Inflammatory Response
Procedure: Laparoscopic resection

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Increased SOCS 3 mRNA in Monocytes From Patients Subjected to Laparoscopic Colon Surgery

Resource links provided by NLM:


Further study details as provided by Oslo University Hospital:

Primary Outcome Measures:
  • Inflammatory values for laparoscopic resection for colon cancer. [ Time Frame: 3 days ] [ Designated as safety issue: No ]
    Corresponding values of SOCS3 mRNA copared to inflammatory cytokines in patients with laparoscopic resection for colon cancer.


Estimated Enrollment: 20
Study Start Date: January 2007
Study Completion Date: December 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Colon cancer patients
Laparoscopic resection
Procedure: Laparoscopic resection
Inflammatory response in laparoscopic surgery
Other Name: Colon cancer

Detailed Description:

Blood samples from 20 patient with colon cancer collected before and in 3 days following laparoscopic surgery. Analyzed for inflammatory cytokines and corresponding SOCS3 mRNA.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Colon cancer stage I-III

Criteria

Inclusion Criteria:Colon cancer stage I-III -

Exclusion Criteria:Colon cancer stage IV

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01419431

Locations
Norway
Oslo University Hospital
Oslo, Norway, 0407
Sponsors and Collaborators
Oslo University Hospital
Investigators
Principal Investigator: Dag T. Førland, MD OUS
  More Information

No publications provided

Responsible Party: Dag T Førland, MD, Oslo University Hospital
ClinicalTrials.gov Identifier: NCT01419431     History of Changes
Other Study ID Numbers: SOCS3 mRNA, SOCS-3-202008
Study First Received: July 18, 2011
Last Updated: December 15, 2011
Health Authority: Norway: Regional Ethics Commitee

Keywords provided by Oslo University Hospital:
Colon cancer

ClinicalTrials.gov processed this record on October 02, 2014